Stocktoria

Neumora Therapeutics, Inc. NMRA

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2023-09-15

Neumora Therapeutics, Inc. statistics & valuation

Market cap$303.9M
P / B2.9×
Net cash$128.0M
Enterprise value USD$175.9M
Earnings yield EBIT/EV-137.1%
Return on capital-152.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2022202320242025
Operating margin (%)
2022202320242025
Return on equity (%)
-50.30% -84.90% -228.10% 2022202320242025
Shares outstanding
32.6M 158.8M 161.7M 174.3M 2022202320242025
Net debt ($)
-$142.1M -$128.0M 2022202320242025
Share buybacks ($)
2022202320242025
Return on assets (%)
-30.70% -47.50% -76.90% -124.00% 2022202320242025
Free cash flow margin (%)
2022202320242025
Debt / equity (×)
0.00× 0.52× 2022202320242025
EPS ($)
-$4.81 -$3.63 -$1.53 -$1.45 2022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022
Return on assets-124.0%-76.9%-47.5%-30.7%
Return on equity-228.1%-84.9%-50.3%29.3%
Debt / equity0.52×0.00×——
Current ratio5.8710.5119.0516.37

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.